Table 6.

JAK1/JAK2 Inhibitors in Development for the Treatment of Patients with Polycythemia Vera

Agent (additional names)	Targeted JAK	Indication	Stage of development
Ruxolitinib	1, 2	MF PV ET Psoriasis (topical)	FDA approved Phase 3 Phase 2 Phase 2
LY2784544	2	MF PV ET	Phase 1/2
Momelotinib (CYT387)	1, 2	MF PV ET	Phase 3 Phase 2
Pacritinib (SB1518)	2	MF Other hematologic malignancies	Phase 3 Phase 1/2
Fedratinib (SAR302503, TG101348)	1, 2	MF PV ET Other malignancies	Discontinued because of reports of Wernicke's encephalopathy

ET indicates essential thrombocythemia; FDA, US Food and Drug Administration; JAK, Janus kinase; MF, myelofibrosis; PV, polycythemia vera.